AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TALPHERA, INC. Director's Dealing 2023

Sep 11, 2023

35181_dirs_2023-09-11_c2cbbaa7-3cce-45c1-86da-40b1b7dd4aba.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2023-09-11

Reporting Person: Angotti Vincent J. (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-11	Common Stock	P	10000	$0.795	Acquired	91805	Direct

Footnotes

F1: Balance includes non-reportable acquisitions of 7,969 and 10,000 shares of Common Stock through the Company's Employee Stock Purchase Plan on February 28, 2023 and August 31, 2023, respectively.